Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 11/20 | 0.33 |
| ▸ | XIAP | P98170 | 10/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 10/20 | 0.33 |
| ▸ | BIRC8 | Q96P09 | 2/20 | 0.33 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815291 | 0.89 | LIPE (0.35) | — | |
| SCHEMBL14815220 | 0.89 | LIPE (0.35) | — | |
| SCHEMBL14815255 | 0.88 | KLRK1 (0.37) | — | |
| SCHEMBL14815239 | 0.88 | KLRK1 (0.37) | — | |
| SCHEMBL14815188 | 0.82 | CCR1 (0.33) | CNR2 | |
| SCHEMBL14815398 | 0.81 | TEAD1 (0.35) | CNR2 | |
| SCHEMBL14815149 | 0.81 | GPR119 (0.32) | GPR119 | |
| SCHEMBL14815140 | 0.81 | TEAD1 (0.36) | — | |
| SCHEMBL14814738 | 0.81 | LIPE (0.35) | CNR2 | |
| SCHEMBL14815287 | 0.81 | KLRK1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | CHRM1 158/4885RAB9A 3469/4885BIRC2 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.